ArticleEuropean journal of nuclear medicine and molecular imaging2018
Performance of FDG-PET/CT in solitary pulmonary nodule based on pre-test likelihood of malignancy: results from the ITALIAN retrospective multicenter trial.
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- [Frontiers in medicine · 2024Pooled it
- EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2022Pooled it
- The Role of F-18 FDG PET/CT in the Evaluation of Solitary Pulmonary Nodules.Saudi medical journal · 2026Article
- Multimodal glyco-lipid-EBVDNA signature prognostic model for individualized risk stratification of locally advanced nasopharyngeal carcinoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer.European radiology · 2026Article
- Hypermetabolic pulmonary lesions detection and diagnosis based on PET/CT imaging and deep learning models.European journal of nuclear medicine and molecular imaging · 2025Article
- Integrating multimodal features to predict the malignancy of pulmonary ground-glass nodules: a multicenter prospective model development and validation study.Frontiers in oncology · 2025Article
- BaselineFrontiers in medicine · 2025Article
- Predicting the invasiveness of pulmonary adenocarcinoma using intratumoral and peritumoral radiomics features.Frontiers in medicine · 2025Article
- Development and validation of a predictive model combining radiomics and deep learning features for spread through air spaces in stage T1 non-small cell lung cancer: a multicenter study.Frontiers in oncology · 2025Article
- The value of 18F-FDG PET/CT combined with 3D quantitative technology and clinicopathological features in predicting prognosis of NSCLC.Frontiers in oncology · 2025Article
- Radiomics based onFrontiers in oncology · 2024Article
- PET/CT-aided biopsy of lung lesions enhances diagnostic efficacy, especially for lesions >3cm.Frontiers in oncology · 2024Article
- Predicting lung cancer's metastats' locations using bioclinical model.Frontiers in medicine · 2024Article
- The metaverse in nuclear medicine: transformative applications, challenges, and future directions.Frontiers in medicine · 2024Review
- Global research hotspots and trends of iodinated contrast agents in medical imaging: a bibliometric and visualization analysis.Frontiers in medicine · 2024Article
- Construction of a risk screening and visualization system for pulmonary nodule in physical examination population based on feature self-recognition machine learning model.Frontiers in medicine · 2024Article
- Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer.European radiology · 2023Article
- Qualitative and Semiquantitative Parameters ofCancers · 2023Article
- Preoperative diagnosis of solitary pulmonary nodules with a novel hematological index model based on circulating tumor cells.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to determine the performance of
methodsFDG-PET/CT of 502 patients, stratified for pre-test cancer risk, were retrospectively analyzed. FDG uptake in SPN was assessed by a 4-point scoring system and semiquantitative analysis using the ratio between SUVmax in SPN and SUVmean in mediastinal blood pool (BP) and between SUVmax in SPN and SUVmean in liver (L). Histopathology and/or follow-up data were used as standard of reference.
resultsSPN was malignant in 180 (36%) patients, benign in 175 (35%), and indeterminate in 147 (29%). The 355 patients with a definitive SPN nature (malignant or benign) were considered for the analysis. Considering FDG uptake ≥ 2, sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, and accuracy were 85.6%, 85.7%, 86%, 85.2%, and 85.6% respectively. Sensitivity and PPV were higher (P < 0.05) in intermediate and high-risk patients, while specificity and NPV were higher (P < 0.05) in low-risk patients. On receiver operating characteristic curve analysis, the cut-offs for better discrimination between benign and malignant SPN were 1.56 (sensitivity 81% and specificity 87%) and 1.12 (sensitivity 81% and specificity 86%) for SUVmax/SUVmeanBP and SUVmax/SUVmeanL respectively. In intermediate and high-risk patients, including the SUVmax/SUVmeanBP, the specificity shifted from 85% and 50% to 100%.
conclusionVisual FDG-PET/CT has an acceptable performance in patients with SPN, but accuracy improves when SUVratios are considered, particularly in patients with intermediate and high risk of malignancy.
Indexed as
Identifiers
29736699What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.